Dr. Reddy’s Laboratories has informed that it enclosed a Press Release ‘Dr. Reddy’s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India’.
The above information is a part of company’s filings submitted to BSE.